Description
What is Renaxen 5 mg?
Renaxen 5 mg is an Axitinib INN tablet manufactured by Everest Pharmaceuticals Ltd. Axitinib is an oral VEGFR tyrosine kinase inhibitor used for advanced renal cell carcinoma. The usual starting dose is 5 mg twice daily, with dose modifications based on tolerability and clinical factors.
What is Axitinib 5 mg used for?
Axitinib 5 mg is used to treat advanced renal cell carcinoma. It can be prescribed alone after previous systemic treatment or as part of approved combination therapy with immunotherapy in first-line advanced RCC.
How does Axitinib work?
Axitinib blocks VEGFR-1, VEGFR-2, and VEGFR-3. These receptors are involved in VEGF signaling and angiogenesis. By inhibiting VEGFR signaling, Axitinib reduces tumor-associated blood-vessel formation.
What is the usual Renaxen 5 mg dose?
The usual starting dose of Axitinib is 5 mg twice daily, taken approximately 12 hours apart. It can be taken with or without food. Doctors may adjust the dose according to treatment response and adverse effects.
What are the main Renaxen 5 mg side effects?
Common Axitinib side effects include hypertension, diarrhea, fatigue, decreased appetite, nausea, dysphonia, hand-foot syndrome, and weight loss. Serious risks include bleeding, blood clots, heart failure, gastrointestinal complications, proteinuria, liver toxicity, and impaired wound healing.
Quick Renaxen 5 mg facts
| Product detail | Information |
| Brand | Renaxen 5 mg |
| Active ingredient | Axitinib INN |
| Strength | 5 mg |
| Dosage form | Oral tablet |
| Therapeutic class | Tyrosine kinase inhibitor |
| Main target | VEGFR-1, VEGFR-2, VEGFR-3 |
| Main established use | Advanced renal cell carcinoma |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack size | 60 tablets |
| Listed shelf life | 24 months |
| Prescription | Required |
| Typical starting dose | 5 mg twice daily |
| Administration | With or without food |
The manufacturer listing confirms Renaxen 5 as Axitinib INN 5 mg.
Renaxen 5 mg Manufacturer and Product Details
Renaxen 5 mg is listed by Everest Pharmaceuticals Ltd. as an Axitinib INN product. Everest’s oncology catalogue includes Renaxen 5 alongside other oncology medicines.
For this product page, the supplied product information identifies:
Manufacturer: Everest Pharmaceuticals Ltd.
Active ingredient: Axitinib INN
Strength: 5 mg
Pack: 60 tablets
Shelf life: 24 months
The supplier/exporter information supplied for this page identifies Emergency Drug as the exporter/supplier.
For international orders, prescription requirements and import rules can vary by destination. A patient should confirm the medicine’s legality by providing a valid prescription and import requirements before placing an order.
Axitinib mechanism of action in simple terms
Tumor releases angiogenic signals → VEGF activates VEGFR → new blood vessels form → tumor receives blood supply.
Axitinib interrupts the pathway:
Axitinib → VEGFR inhibition → reduced angiogenic signaling → reduced tumor blood-vessel formation.
This is why Axitinib belongs to the antiangiogenic targeted therapy group.
Does Axitinib kill cancer cells directly?
Not in the same way as traditional cytotoxic chemotherapy.
Its main action is targeted inhibition of VEGF receptor signaling. This interferes with the tumor’s ability to develop and maintain the blood-vessel network that supports growth.
The clinical effect is measured through outcomes such as tumor response, progression-free survival, and overall survival.
FDA Approved Axitinib (Renaxen 5 mg)
The primary established indication for Axitinib is advanced renal cell carcinoma.
The current FDA prescribing information lists Axitinib for:
- First-line advanced RCC in combination with avelumab.
- First-line advanced RCC in combination with pembrolizumab.
- Advanced RCC after failure of one prior systemic therapy when used as a single agent.
The National Cancer Institute similarly lists axitinib for advanced RCC, either with avelumab or pembrolizumab as initial treatment or alone after one prior systemic treatment.
The exact indication for a Renaxen product depends on its regulatory approval in the country where it is supplied.
Renaxen 5 mg for advanced renal cell carcinoma
Renal cell carcinoma is the most common form of kidney cancer in adults.
Advanced RCC can involve cancer that has spread beyond the kidney or cannot be removed completely with surgery.
Treatment selection depends on factors such as:
- RCC subtype
- Disease stage
- Previous treatment
- IMDC risk group
- General health
- Kidney and liver function
- Other medical conditions
- Previous immunotherapy or targeted therapy
An oncologist should select the treatment regimen.
Renaxen 5 mg and Advanced Renal Cell Carcinoma
Axitinib has an established role in the treatment of advanced RCC.
Its role has changed as modern combination therapies have become more common.
For example, pembrolizumab plus axitinib produced better overall survival and progression-free survival than sunitinib in the KEYNOTE-426 trial. With a median follow-up of 30.6 months, median overall survival was not reached with pembrolizumab plus axitinib versus 35.7 months with sunitinib. Median progression-free survival was 15.4 versus 11.1 months.
The FDA label therefore includes pembrolizumab plus Axitinib as a first-line option for advanced RCC.
This does not mean that every patient with RCC should receive Axitinib. Treatment must be individualized.
Renaxen 5 mg Dose and Administration
The usual starting dose of Axitinib as a single agent is:
- 5 mg orally twice daily.
The doses should be taken approximately 12 hours apart.
Axitinib can be taken with or without food. The tablet should be swallowed whole with a glass of water.
Example dosing schedule:
A patient taking Axitinib twice daily might take the medicine at:
- 8:00 AM
- 8:00 PM
The exact schedule should follow the prescribing physician’s instructions.
What if a dose is missed?
Patients should not double the next dose unless specifically instructed by their healthcare professional.
If vomiting occurs after taking a dose, an additional dose should not automatically be taken. The next scheduled dose should generally be taken at the usual time. Product information for Axitinib gives the same general instruction.
Renaxen 5 mg Dose Adjustments
The 5 mg twice-daily dose is a starting point, not a guaranteed lifelong dose.
A clinician may reduce or interrupt treatment when adverse effects occur.
The Axitinib prescribing information allows dose modification based on individual safety and tolerability. Under appropriate circumstances, patients who tolerate treatment may have their dose increased to 7 mg twice daily and then 10 mg twice daily.
Dose reduction may also be required.
This is important:
Do not increase, reduce, stop, or restart Renaxen without instructions from the treating oncology team.
The correct dose is the dose that balances cancer control with tolerability.
Renaxen 5 mg Side Effects
Axitinib can cause side effects because VEGF signaling is also involved in normal vascular function.
The most common adverse reactions reported with single-agent Axitinib include:
- Diarrhea
- Hypertension
- Fatigue
- Reduced appetite
- Nausea
- Dysphonia or hoarseness
- Hand-foot syndrome
- Weight loss
- Vomiting
- Weakness
- Constipation
These are listed in the FDA prescribing information.
Hypertension
High blood pressure is one of the most important adverse effects to monitor.
Blood pressure should be controlled before treatment starts.
Patients should monitor their blood pressure according to their oncology team’s instructions.
Severe hypertension can require treatment interruption, dose reduction, or permanent discontinuation.
Diarrhea
Diarrhea is common with Axitinib.
Patients should tell their healthcare team if diarrhea becomes persistent, severe, or associated with dehydration.
Drinking enough fluid is important unless the treating team has imposed fluid restrictions.
Hand-foot syndrome
Palmar-plantar erythrodysesthesia can cause redness, tenderness, burning, swelling, or peeling of the hands and feet.
Early reporting helps the clinical team manage symptoms before they become severe.
Fatigue
Fatigue can affect daily activities.
Patients should balance activity with rest and tell their oncology team if fatigue becomes severe or sudden.
Hoarseness
Dysphonia can occur during treatment.
Persistent voice changes should be reported, particularly when they affect swallowing or breathing.
Serious Warnings and Precautions
Axitinib has important safety warnings.
Hypertension
Severe hypertension and hypertensive crisis have been reported.
Blood pressure should be monitored during therapy.
Arterial and venous blood clots
Arterial and venous thromboembolic events have occurred.
Patients with cardiovascular or clotting risk factors need careful assessment.
Hemorrhage
Serious and sometimes fatal bleeding has been reported.
Patients with active bleeding or certain high-risk conditions require special consideration.
Cardiac failure
Heart failure has been reported and can be serious.
New or worsening shortness of breath, swelling, unusual fatigue, or rapid weight gain should be assessed promptly.
Gastrointestinal perforation and fistula
Rare but serious gastrointestinal complications can occur.
Severe abdominal pain, persistent vomiting, fever, or other acute abdominal symptoms require urgent medical evaluation.
Thyroid dysfunction
Hypothyroidism can occur.
Thyroid function should be checked before treatment and periodically during therapy.
Proteinuria
Protein in the urine can occur during treatment.
Urine protein should be assessed before treatment and periodically during therapy.
Liver toxicity
Liver enzyme abnormalities can occur.
ALT, AST, and bilirubin should be monitored. More frequent monitoring may be needed when Axitinib is combined with pembrolizumab or avelumab.
Wound healing
Axitinib can impair wound healing.
⚠️The FDA label recommends withholding Axitinib for at least 2 days before elective surgery and avoiding administration for at least 2 weeks after major surgery until adequate wound healing has occurred.
👉Patients should always tell their surgeon and oncologist that they are taking Axitinib.
When Should a Patient Call a Doctor?
Patients should seek urgent medical attention for symptoms such as:
- Severe chest pain
- Sudden shortness of breath
- Severe headache or neurological symptoms
- Fainting
- Heavy or unusual bleeding
- Severe abdominal pain
- Black or bloody stools
- Sudden weakness or difficulty speaking
- Severe or uncontrolled blood pressure
- Signs of a serious allergic reaction
⚠️Do not wait for the next oncology appointment when a potentially serious reaction occurs.
Axitinib Drug Interactions
Axitinib is metabolized mainly through CYP3A4/5.
Strong CYP3A4/5 inhibitors can increase Axitinib exposure.
Strong CYP3A4/5 inducers can reduce Axitinib exposure.
The FDA label recommends avoiding strong inhibitors and inducers when possible. If a strong inhibitor is unavoidable, the Axitinib dose may need to be reduced.
Medicines that deserve special attention
Patients should tell their doctor about:
- Antibiotics
- Antifungal medicines
- HIV medicines
- Antiseizure medicines
- Herbal supplements
- Anticoagulants
- Blood pressure medicines
- Corticosteroids
- Other cancer medicines
❌Grapefruit or grapefruit juice may also increase Axitinib exposure and should be avoided according to Axitinib product information.
❎Never assume that an over-the-counter medicine or supplement is safe to combine with cancer treatment.
Monitoring During Renaxen Treatment
Monitoring is part of treatment. A typical monitoring plan or checklist may include:
| What is monitored | Why it matters |
| Blood pressure | Detect hypertension |
| Urine protein | Detect proteinuria |
| Liver enzymes | Detect hepatotoxicity |
| Bilirubin | Assess liver function |
| Thyroid function | Detect thyroid dysfunction |
| Symptoms | Identify adverse reactions |
| Weight and appetite | Track nutritional effects |
| Cardiac symptoms | Identify possible heart failure |
| Imaging | Assess tumor response |
| Blood tests | Support overall treatment monitoring |
The exact monitoring schedule is determined by the oncology team.
Renaxen 5 mg vs Axinix 5 mg Comparison
One of the common searches around this medicine is:
What is the alternative to Axinix 5 mg?
Axinix 5 mg contains Axitinib 5 mg and is manufactured & marketed by Beacon Pharmaceuticals. Its prescribing information identifies VEGFR-1, VEGFR-2, and VEGFR-3 as important targets and gives 5 mg twice daily as the recommended starting dose. Axinix 5 is also listed as a 60-tablet pack.
Renaxen 5 mg also contains Axitinib INN 5 mg and is listed by Everest Pharmaceuticals Ltd.
| Feature | Renaxen 5 mg | Axinix 5 mg |
| Active ingredient | Axitinib INN | Axitinib |
| Strength | 5 mg | 5 mg |
| Drug family | VEGFR tyrosine kinase inhibitor | VEGFR tyrosine kinase inhibitor |
| Manufacturer | Everest Pharmaceuticals Ltd. | Beacon Pharmaceuticals |
| Listed pack | 60 tablets | 60 tablets |
| Main established indication | Advanced RCC | Advanced RCC |
| Typical starting dose | 5 mg twice daily | 5 mg twice daily |
| Regulatory status | Depends on destination | Depends on destination |
The two products contain the same active ingredient and strength, but patients should not assume automatic therapeutic interchangeability without prescribing by a physician. These two products are made in Bangladesh and maintain cGMP for producing these two medicines by their respective manufacturer..
Renaxen 5 mg (The Generic) vs Inlyta (The Brand)
Inlyta is the original branded Axitinib product from Pfizer whereas Renaxen is an Axitinib generic product listed by Everest Pharmaceuticals.
The active ingredient is the key pharmacological component, but generic products should be sourced through legitimate pharmaceutical channels and used according to local regulatory requirements.
In the United States, Inlyta remains a high-cost branded product. Drugs.com currently lists a cash price of about approx. $20,678.94 for 60 of the 5 mg tablets. Pfizer’s statutory disclosures define WAC as the manufacturer’s published wholesale list price before discounts or rebates, and note that WAC can differ substantially from the amount actually paid by patients.
For this reason, a statement such as “Axitinib costs approx. $7,090 in the United States” should not be presented as a universal current price without a dated source.
Why can generic Axitinib cost less?
Generic pharmaceutical products can have substantially lower acquisition prices than branded products because they do not carry the same originator development and market-exclusivity costs.
However, price alone does not prove quality.
Patients should verify:
- Manufacturer identity
- Product strength
- Batch information
- Expiry date
- Packaging
- Prescription requirements
- Regulatory status
- Supplier credentials
- Import requirements
Axitinib vs Other VEGFR Inhibitors
Axitinib belongs to the broader VEGFR tyrosine kinase inhibitor family.
Other targeted therapies used in RCC include:
- Sunitinib
- Pazopanib
- Sorafenib
- Cabozantinib
- Lenvatinib
- Tivozanib
They are not identical medicines.
Their kinase targets, indications, adverse-effect profiles, dosing schedules, and approved combinations differ.
Comparison of selected RCC targeted therapies
| Medicine | Main pathway | Common RCC role | Key practical issue |
| Axitinib | VEGFR-1/2/3 | Advanced RCC; combinations and later-line use | Hypertension, diarrhea, fatigue |
| Sunitinib | VEGFR, PDGFR, KIT and others | RCC | Fatigue, hand-foot syndrome, hypertension |
| Pazopanib | VEGFR, PDGFR, FGFR and others | RCC | Liver monitoring is important |
| Cabozantinib | VEGFR, MET, AXL and others | RCC | Diarrhea, fatigue, hand-foot syndrome |
| Lenvatinib | VEGFR, FGFR and others | RCC combinations | Hypertension, diarrhea, renal/hepatic effects |
| Tivozanib | VEGFR | RCC | Hypertension and fatigue |
The best option depends on the patient’s treatment history and clinical profile.
There is no universal “strongest” VEGFR inhibitor.
Clinical Evidence for Axitinib
Clinical evidence is one of the most important reasons to distinguish Axitinib from an untested cancer product.
AXIS trial
The phase III AXIS trial compared Axitinib with sorafenib in patients with advanced RCC after prior systemic therapy.
The study enrolled 723 patients.
Median investigator-assessed progression-free survival was:
- 8.3 months with Axitinib
- 5.7 months with sorafenib
The hazard ratio was 0.656, favoring Axitinib for PFS. Median overall survival was 20.1 months with Axitinib and 19.2 months with sorafenib, with no statistically significant difference in overall survival.
This is an important distinction.
Axitinib demonstrated a clear PFS advantage in the AXIS trial, but the trial did not demonstrate a statistically significant overall-survival advantage.
First-line comparison with sorafenib
A separate phase III trial studied previously untreated metastatic RCC.
Median PFS was 10.1 months with Axitinib and 6.5 months with sorafenib, but the difference did not reach statistical significance. Objective response rate was higher with Axitinib, 32% versus 15%.
This helps explain why Axitinib’s clinical role should not be reduced to a simple “better than every alternative” claim.
Pembrolizumab plus Axitinib
KEYNOTE-426 evaluated pembrolizumab plus Axitinib against sunitinib in untreated advanced RCC.
The combination showed sustained improvements in overall survival and progression-free survival.
At approximately 30.6 months of follow-up:
- Median PFS: 15.4 vs 11.1 months
- Overall survival hazard ratio: 0.68
- PFS hazard ratio: 0.71
The study supported pembrolizumab plus Axitinib as a first-line treatment option for advanced RCC.
Avelumab plus Axitinib
JAVELIN Renal 101 also demonstrated improved PFS with avelumab plus Axitinib compared with sunitinib.
In an updated analysis, median PFS in the overall population was 13.3 months with avelumab plus Axitinib versus 8.0 months with sunitinib.
Longer-term follow-up showed that the overall survival difference was not statistically significant in the final analysis, although median OS remained numerically longer with the combination.
This is a useful example of why medical content should report both positive findings and limitations.
Clinical Data at a Glance
Evidence summary
| Study | Population | Treatment | Key finding |
| AXIS | Previously treated advanced RCC | Axitinib vs sorafenib | PFS 8.3 vs 5.7 months |
| First-line phase III | Untreated metastatic RCC | Axitinib vs sorafenib | ORR 32% vs 15%; PFS difference not statistically significant |
| KEYNOTE-426 | Untreated advanced RCC | Pembrolizumab + Axitinib vs sunitinib | PFS and OS benefit |
| JAVELIN Renal 101 | Untreated advanced RCC | Avelumab + Axitinib vs sunitinib | PFS benefit |
These studies support the clinical relevance of Axitinib, but trial results should not be used to predict an individual patient’s outcome.
Renaxen 5 mg Price and Cost Considerations
Renaxen 5 mg pricing varies according to:
- Destination country
- Quantity ordered
- Shipping method
- Local import requirements
- Supplier pricing
- Currency exchange rates
- Prescription and documentation requirements
The product information supplied for this page uses a quotation-based model rather than a fixed public retail price.
This makes international generic sourcing relevant for some patients, but price should never be considered separately from legality, product quality, prescription status, and clinical supervision.
Buying Renaxen 5 mg Safely
Renaxen 5 mg is a prescription medicine.
A safer purchasing pathway includes:
- Obtain a valid prescription from the treating physician.
- Confirm that Axitinib is appropriate for the patient’s treatment plan.
- Verify the exact strength and pack size.
- Confirm the manufacturer’s name.
- Check the expiry date and packaging.
- Ask for batch or product verification where available.
- Confirm shipping and import requirements.
- Use tracked pharmaceutical delivery where appropriate.
- Do not purchase from sellers offering suspiciously cheap products without verification.
- Keep the medicine in its original packaging.
Emergency Drug states that it supplies generic medicines internationally and works with manufacturers including Everest Pharmaceuticals. Its website also states that delivery timelines can range from 5 to 20 days depending on destination and shipping conditions.
The supplier/exporter identified for this product is Emergency Drug.
Emergency Drug official website
Export destinations
The supplied product brief identifies these target markets:
- Saudi Arabia
- United Arab Emirates
- Qatar
- Kuwait
- Bahrain
- Oman
- Yemen
- Jordan
- Lebanon
- Syria
- Egypt
- Turkey
- Australia
- New Zealand
International pharmaceutical import rules differ by country.
A shipment that is permitted in one country may require additional documentation or authorization in another.
Patients should check local rules before ordering.
How to Request a Renaxen 5 mg Quote
For a prescription medicine, a practical quote request should include:
- Patient country
- Required strength
- Quantity
- Prescription status
- Preferred shipping method
- Any required delivery deadline
The supplier can then confirm current availability, pricing, shipping charges, documentation, and delivery conditions.
Prices should be treated as time-sensitive.
Patient Reviews and Real-World Experience
Patient reviews can help explain what treatment feels like.
They cannot replace clinical evidence.
For example, public review sites contain limited patient feedback about branded Axitinib. According to Drugs.com currently shows only a very small number of user ratings for Inlyta, so those ratings should not be treated as representative clinical data.
Online communities also contain individual reports about Axitinib side effects and treatment experiences. One recent Reddit discussion described severe gastrointestinal symptoms during pembrolizumab plus Axitinib treatment, while another described hand-foot symptoms and taste changes. These are individual experiences, not controlled evidence.
What patients should learn from reviews
Patient reports can help you recognize questions to ask your healthcare team:
- How should diarrhea be managed?
- When should a dose be held?
- How often should blood pressure be checked?
- What should I do about hand-foot symptoms?
- Which medicines should I avoid?
- What symptoms require urgent care?
But one patient’s experience cannot predict another patient’s response.
Practical Patient Tips for Renaxen 5 mg
Keep a blood pressure record
- Write down readings regularly.
- Bring the record to oncology appointments.
Keep a medication list
- Include prescription drugs, OTC products, vitamins, and herbal supplements.
Protect hands and feet
- Tell your care team about redness, burning, swelling, pain, or skin peeling.
Watch hydration
- Diarrhea and vomiting can cause dehydration.
- Seek medical advice if symptoms become significant.
Tell your surgeon
- Axitinib can affect wound healing.
- Always disclose treatment before a planned procedure.
Do not change the dose yourself
- Axitinib dose changes require clinical assessment.
Take the medicine consistently
- Try to maintain approximately 12-hour intervals.
Pregnancy and Breastfeeding
Axitinib can cause fetal harm.
Patients who could become pregnant should discuss effective contraception with their healthcare professional.
⚠️The FDA label advises against breastfeeding during Axitinib treatment.
The exact contraception duration after treatment should be based on the current prescribing information applicable to the product and the advice of the treating clinician.
Storage of Renaxen 5 mg
Follow the manufacturer’s storage instructions on the package.
The supplied Renaxen product information states:
- Store below 30°C.
- Protect from moisture.
- Protect from direct sunlight.
- Keep the medicine in its original package.
- Keep out of reach of children.
Do not use tablets that are damaged, discolored, or otherwise appear abnormal without first checking with a pharmacist.
Frequently Asked Questions About Renaxen 5 mg
- What is Renaxen 5 mg used for?
Ans: Renaxen 5 mg contains Axitinib INN, a VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma. Axitinib can be used alone after failure of one prior systemic therapy and in approved combinations with immunotherapy in first-line advanced RCC.
- Is Renaxen 5 mg the same as Axitinib 5 mg?
Ans: Renaxen 5 mg is a brand/product containing Axitinib INN 5 mg. The active ingredient is Axitinib. Product interchangeability should still be confirmed according to local regulatory and prescribing requirements.
- What is the usual Axitinib 5 mg dose?
Ans: The usual starting dose is 5 mg twice daily, approximately 12 hours apart. It can be taken with or without food. The dose may be modified according to tolerability and other clinical factors.
- Is Axinix 5 mg an alternative to Renaxen 5 mg?
Ans: Axinix 5 mg is another Axitinib 5 mg product. Beacon Pharmaceuticals lists Axinix 5 as containing Axitinib 5 mg in a 60-tablet pack. Because the products are manufactured by different companies, patients should confirm regulatory status and suitability with their prescriber or pharmacist before switching.
5.How much does Renaxen 5 mg cost?
Ans: The price depends on the supplier, country, quantity, shipping, and import requirements.
Key Takeaways About Renaxen 5 mg
- Renaxen 5 mg contains Axitinib INN.
- Axitinib is a targeted VEGFR tyrosine kinase inhibitor.
- Its main targets are VEGFR-1, VEGFR-2, and VEGFR-3.
- Its established clinical role is in advanced renal cell carcinoma.
- The usual starting dose is 5 mg twice daily.
- Blood pressure, liver function, thyroid function, urine protein, and treatment-related symptoms require monitoring.
- Important risks include hypertension, bleeding, blood clots, cardiac failure, gastrointestinal complications, impaired wound healing, proteinuria, hepatotoxicity, and thyroid dysfunction.
- Axitinib has substantial clinical evidence from phase III trials, including AXIS, KEYNOTE-426, and JAVELIN Renal 101.
Conclusion: Is Renaxen 5 mg Right for You?
Renaxen 5 mg is an Axitinib-based targeted cancer medicine designed to block VEGFR signaling.
Its value comes from a well-established mechanism and clinical evidence in advanced renal cell carcinoma.
The medicine is not suitable for self-treatment.
The right treatment depends on cancer type, treatment history, disease progression, other medicines, blood pressure, liver function, cardiovascular risk, and overall health.
If your oncologist has prescribed Axitinib 5 mg and you are comparing branded and generic options, check the active ingredient, strength, manufacturer, pack size, regulatory status, prescription requirements, and total delivered cost before making a decision.
For patients seeking an international supply option, Emergency Drug identifies itself as an exporter of generic medicines and states that it works with manufacturers including Everest Pharmaceuticals. Its published shipping information states that delivery can take approximately 5 to 20 days depending on destination and shipping conditions.
Before ordering, provide a valid prescription and confirm that importing the medicine is permitted in your country.
Product Trust Statement
Product: Renaxen 5 mg
Active ingredient: Axitinib INN 5 mg
Manufacturer: Everest Pharmaceuticals Ltd.
Pack size: 60 tablets
Supplier/Exporter: Emergency Drug
Prescription: Required
Use: Advanced renal cell carcinoma, according to applicable regulatory approval
Prices, availability, packaging, registration status, and shipping times can change. Always verify the current product information before purchase.
Need a current Renaxen 5 mg quotation? Request the latest price, availability, shipping cost, and documentation requirements for your destination rather than relying on an old online price.
⚠️IMPORTANT MEDICAL NOTICE
💊Renaxen 5 mg is a prescription cancer medicine. This page provides educational information and does not replace advice from an oncologist, pharmacist, or other qualified healthcare professional. The correct dose, treatment combination, monitoring schedule, and duration depend on the patient’s cancer, previous treatment, liver function, other medicines, and treatment response.
